Could an inhaled sedative quiet the Brain's migraine alarm?

NCT ID NCT07769255

NEW Recruiting now Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether inhaling a sedative called dexmedetomidine can reduce the brain's oversensitivity that drives chronic migraine. Researchers will measure changes in pain-related biomarkers and nerve signals in people with early chronic migraine. The goal is to see if this non-invasive approach can ease symptoms and slow the progression of the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nebulized dexmedetomidine, a sedative drug given as a mist to inhale
What this could lead to: If it works, this could offer a non-invasive, needle-free way to treat chronic migraine and possibly prevent it from worsening.
What could go wrong: This is an early-stage trial, so the drug may not prove effective or safe for migraine. It may also cause sedation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE

Contacts and locations

Locations

Beni-Suef University Hospital
RECRUITING

Banī Suwayf, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.